Memantine XR for Stroke

Recruiting in Palo Alto (17 mi)

Overseen ByAlicia Bennett, D.O.

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: University of Utah

Trial Summary

What is the purpose of this trial?This will be a randomized double blind placebo-controlled pilot study using a repeated measures design in which participants with acute ischemic stroke and upper extremity weakness are randomized to either drug or placebo

Eligibility Criteria

This trial is for adults over 18 who lived independently before having an ischemic stroke, can swallow pills, and have arm weakness needing therapy. They must be within 3 days to 8 weeks of their stroke, able to move the affected arm, and have a confirmed supratentorial stroke with certain Fugl-Meyer scores.

Participant Groups

The study tests if Memantine XR helps in recovery from acute ischemic stroke compared to a placebo. Participants are randomly assigned to either the drug or placebo group without knowing which one they receive (double-blind).

2Treatment groups

Active Control

Placebo Group

Group I: Memantine plus standard of careActive Control1 Intervention

Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will use a titration schedule starting at 7mg daily for 1 week, increasing by 7mg (1 capsule) per week until at a goal dose of 28mg daily (goal dose) as recommend by the manufacturer. Participants will continue memantine for 90 days. Continue with standard care for stroke.

Group II: Placebo plus standard of carePlacebo Group1 Intervention

Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will titrate up on the dose of placebo until taking twice daily. Participants will continue for 90 days with placebo. Continue with standard of care for other treatment of stroke.